AdventHealth

Industry / private company

Location: Orlando, FL

ISNI: 0000000404477121

ROR: https://ror.org/02n1cyj49

Show on Map:

Publications

(17)

Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial (2020) Mosenzon O, Bain SC, Heerspink HJL, Idorn T, Mann J, Persson F, Pratley RE, et al. Journal article Estimated GFR (eGFR) loss with glucagon-like peptide-1 (GLP-1) analogue treatment: data from SUSTAIN 6 and LEADER (2019) Perkovic V, Bain SC, Bakris G, Buse JB, Gondolf T, Idorn T, Lausvig N, et al. Conference contribution Impact of microvascular disease on cardiorenal outcomes in type 2 diabetes: an analysis from the LEADER and SUSTAIN 6 clinical trials (2019) Zinman B, Verma S, Bain SC, Honore JB, Mann J, Nauck MA, Pratley R, et al. Conference contribution EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES - A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS (2019) Perkovic V, Bain S, Bakris G, Buse J, Idorn T, Mahaffey K, Marso S, et al. Conference contribution EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) - A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER (2019) Perkovic V, Bain S, Bakris G, Buse J, Idorn T, Mahaffey K, Marso S, et al. Conference contribution EGFR LOSS WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUE TREATMENT: DATA FROM SUSTAIN 6 AND LEADER (2019) Perkovic V, Bain S, Bakris G, Buse J, Gondolf T, Idorn T, Lausvig N, et al. Conference contribution PATELLOFEMORAL MORPHOLOGY MEASUREMENTS AND THEIR ASSOCIATIONS WITH TIBIOFEMORAL OSTEOARTHRITIS PROGRESSION: EXPLORATORY ANALYSIS ON THE OSTEOARTHRITIS INITIATIVE (2019) Haj-Mirzaian A, Guermazi A, Pishgar F, Roemer F, Sereni C, Hakky M, Zikria B, Demehri S Conference contribution

‹ 1 2 ›